Does the Her-2 status alter from the primary breast tumour to the lymph node metastasis?
Cardiff Metropolitan University
MetadataShow full item record
Breast cancer affects approximately 45,000 women in the UK each year. Her-2/neu is found to be over-expressed in approximately 20 to 25% of breast cancer. Due to this treatments directed against to Her-2/neu have been developed such as Trastuzumab. Testing of the patients tumour for over-expression of Her-2/neu is performed on the primary tumour but testing of the lymph node metastasis could provide to be more beneficial to the patient. In the study 47 patients were tested, for the Her-2/neu status of the primary tumour and the axillary lymph node metastasis. Testing was performed by IHC using the 4B5 antibody (Ventana) and slides scored under current guidelines of 0, +1, +2 and +3. There were in total l5 changes from the primary tumour and the lymph node metastasis all ranging from either being down-graded or up-graded. Of the l5 changes, 7 changes resulted in being up-graded from their original Her-2/neu status. Statistical results showed that there was no significant changes in the Her-2/neu status from the primary tumour and the axillary lymph node.
MSc Biomedical Science
Showing items related by title, author, subject and abstract.
Prostate specific antigen (PSA): A comparative study of the specificity and sensitivity of monoclonal and polyclonal antibodies in routine processed tissue immunohistochemistry. Robinson, Martyn David (Cardiff Metropolitan University, 2010)Introduction - Prostate Specific Antigen (PSA) is a 34kD glycoprotein produced almost exclusively by the epithelial cells of the prostate. Antibodies directed towards PSA are used in routine immunohistochemistry to demonstrate ...
Inflammation in cultured human epithelial cells after installation of carbon black pollution particles Morgan, Steffan (Cardiff Metropolitan University, 2017-06-01)Introduction Carbon black particles are produced by incomplete combustion or thermal decomposition of hydrocarbons in industry and have numerous applications in both commercial and consumer products (Long et al., 2013). ...
An evaluation of EGFR, E Cadherin, Cyclin D1, p53 and p63 marker expression using a tissue microarray of head and neck squamous cell carcinoma cases Grindley, Kate (Cardiff Metropolitan University, 2010)Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cause of cancer and in the UK in 2006, 5,325 people were diagnosed with oral cancer. The average 5-year survival rate for cancer of the oral cavity is ...